TRAW – traws pharma, inc. (US:NASDAQ)
Stock Stats
News
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Traws Pharma (NASDAQ:TRAW) was upgraded by analysts at LADENBURG THALM/SH SH to a "strong-buy" rating.
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza [Yahoo! Finance]
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
Form 8-K Traws Pharma, Inc. For: Feb 19
Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Ikarian Capital, LLC
Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Squadron Capital Management LLC
Form SCHEDULE 13G Traws Pharma, Inc. Filed by: Adage Capital Management, L.P.
Form SCHEDULE 13G/A Traws Pharma, Inc. Filed by: Ayrton Capital LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.